12,725 Shares in Dianthus Therapeutics, Inc. $DNTH Purchased by PSP Research LLC

PSP Research LLC acquired a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 12,725 shares of the company’s stock, valued at approximately $524,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DNTH. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after purchasing an additional 618 shares during the last quarter. American Century Companies Inc. increased its position in Dianthus Therapeutics by 13.2% during the second quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock worth $1,009,000 after purchasing an additional 6,323 shares during the last quarter. Invesco Ltd. increased its position in Dianthus Therapeutics by 31.1% during the second quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock worth $390,000 after purchasing an additional 4,962 shares during the last quarter. Alliancebernstein L.P. increased its position in Dianthus Therapeutics by 14.5% during the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after purchasing an additional 149,200 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Dianthus Therapeutics during the second quarter worth about $27,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH opened at $85.67 on Wednesday. The firm has a 50 day simple moving average of $85.55 and a 200-day simple moving average of $59.22. Dianthus Therapeutics, Inc. has a one year low of $16.64 and a one year high of $96.50. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of -20.74 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Equities analysts predict that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other news, EVP Ryan Savitz sold 114,367 shares of the firm’s stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total value of $9,492,461.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Edward Carr sold 43,682 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $3,559,646.18. The SEC filing for this sale provides additional information. In the last three months, insiders sold 323,021 shares of company stock worth $26,564,008. 3.02% of the stock is owned by company insiders.

Analysts Set New Price Targets

DNTH has been the subject of a number of recent analyst reports. Raymond James Financial upgraded shares of Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price target for the company from $63.00 to $123.00 in a research report on Tuesday, March 10th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Monday, April 20th. Wells Fargo & Company initiated coverage on shares of Dianthus Therapeutics in a research report on Thursday, March 19th. They set an “overweight” rating and a $135.00 price target for the company. Finally, William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $117.82.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.